TCM Biotech International Corp. (TPE:4169)
Taiwan · Delayed Price · Currency is TWD 149.00
-1.50 (-1.00%)
Sep 8, 2026, 1:30 PM CST
TCM Biotech International Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,898 | 10,215 | 3,419 | 3,437 | 1,502 | 1,819 | |
Market Cap Growth | 65.97% | 198.79% | -0.52% | 128.87% | -17.43% | 6.17% |
Enterprise Value | 8,718 | 9,738 | 2,966 | 3,518 | 1,592 | 1,930 |
Last Close Price | 149.00 | 172.78 | 57.62 | 57.63 | 29.05 | 35.63 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 532.89 | 162.73 | 185.02 | 82.21 | 970.95 |
Forward PE | 111.61 | 89.63 | 42.57 | 99.49 | - | - |
PS Ratio | 14.11 | 14.90 | 5.13 | 3.54 | 1.87 | 2.59 |
PB Ratio | 5.06 | 9.68 | 3.23 | 3.26 | 2.80 | 3.51 |
P/TBV Ratio | 5.08 | 9.70 | 3.24 | 3.28 | 2.85 | 3.60 |
P/FCF Ratio | - | 294.86 | 21.45 | - | 30.98 | 162.55 |
P/OCF Ratio | - | 275.12 | 20.42 | - | 28.74 | 118.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.43 | 14.21 | 4.45 | 3.63 | 1.98 | 2.75 |
EV/EBITDA Ratio | - | 265.44 | 103.67 | 89.02 | 38.95 | 117.57 |
EV/EBIT Ratio | - | 522.04 | 277.32 | 157.56 | 62.91 | 905.86 |
EV/FCF Ratio | - | 281.08 | 18.61 | - | 32.84 | 172.54 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.04 | 0.04 | 0.11 | 0.29 | 0.31 |
Debt / EBITDA Ratio | - | 0.92 | 1.33 | 2.71 | 3.60 | 8.66 |
Debt / FCF Ratio | - | 1.07 | 0.27 | - | 3.25 | 14.39 |
Net Debt / Equity Ratio | -0.60 | -0.48 | -0.46 | -0.37 | 0.13 | 0.20 |
Net Debt / EBITDA Ratio | 56.12 | -13.84 | -17.11 | -9.84 | 1.65 | 6.26 |
Net Debt / FCF Ratio | 96.67 | -14.66 | -3.07 | 9.37 | 1.39 | 9.18 |
Asset Turnover | 0.42 | 0.57 | 0.53 | 0.89 | 0.95 | 0.88 |
Inventory Turnover | 2.24 | 2.56 | 1.99 | 2.44 | 1.79 | 1.67 |
Quick Ratio | 10.17 | 6.06 | 8.24 | 3.87 | 1.42 | 1.42 |
Current Ratio | 11.68 | 7.47 | 9.91 | 4.95 | 2.29 | 2.67 |
Return on Equity (ROE) | -2.09% | 1.81% | 1.99% | 2.33% | 3.46% | 0.36% |
Return on Assets (ROA) | -1.46% | 0.98% | 0.53% | 1.28% | 1.88% | 0.17% |
Return on Invested Capital (ROIC) | -5.92% | 2.87% | 1.45% | 2.96% | 3.26% | 0.29% |
Return on Capital Employed (ROCE) | -2.00% | 1.70% | 1.00% | 2.00% | 4.00% | 0.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.32% | 0.19% | 0.61% | 0.54% | 1.22% | 0.10% |
FCF Yield | -0.12% | 0.34% | 4.66% | -1.21% | 3.23% | 0.61% |
Dividend Yield | 0.24% | 0.21% | 0.61% | 0.50% | 0.11% | - |
Payout Ratio | - | 107.81% | 80.10% | 8.71% | - | 903.20% |
Buyback Yield / Dilution | -3.10% | 0.02% | -11.37% | -8.03% | -0.89% | -0.42% |
Total Shareholder Return | -2.86% | 0.23% | -10.76% | -7.54% | -0.77% | -0.42% |